ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%. The difference in remission rate between the two groups was statistically significant>New Orleans by Satish Keshav, M.D., Ph.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University.
The results from the Maintenance period of PROTECT-1 reported here confirmed and expanded the efficacy of Traficet-EN that was observed in the preceding Induction period of the study, which was reported in 2009.
"Treatment for inflammatory diseases of the bowel including Crohn's has been woefully insufficient for far too long for such a devastating disease," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We believe Traficet-EN represents a paradigm shift in terms of safety and efficacy for these patients, offering the possibility of maintaining remission without the serious complications associated with the current standard of care. Additionally, these data provide a powerful validation of targeting the chemokine system to treat major inflammatory and autoimmune diseases."
Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies